IHH Healthcare is aiming to increase its stake in Fortis Healthcare to 50% over the medium term, reinforcing its commitment to India as a priority market. CEO Prem Kumar Nair said the resolution of the open offer issue creates room for further investment to scale Fortis into a leading healthcare provider.
The company plans to expand its capacity to 10,000 beds by 2030, with a strong emphasis on maintaining high clinical standards rather than pursuing rapid expansion. IHH has allocated ₹2,500 crore over the next three years, focusing on upgrading existing Fortis facilities and integrating Gleneagles hospitals into its network, which currently includes 36 hospitals.
Ashok Pandit highlighted that IHH currently holds about 31% in Fortis and sees higher ownership as key to boosting earnings. Fortis has shown strong financial improvement, with EBITDA margins of 23–24% and consistent growth in revenue and profitability over recent years.
IHH’s early investment made at around ₹170 per share has delivered significant returns, with the stock now trading close to ₹800. The company also continues to refine its diagnostics arm, Agilus, positioning it as a premium genomics-focused brand despite earlier rebranding costs.
